Vertex reported a strong commercial rebound for Casgevy, the CRISPR‑based gene editing therapy marketed with CRISPR Therapeutics, with sales more than tripling sequentially. Management framed the product’s performance as a bright spot amid broader company updates and investor scrutiny. Analysts pointed to Casgevy as a proof point for clinical and commercial viability of in vivo gene editing approaches, and the sales uptick was highlighted in earnings commentary as a stabilizing factor for Vertex’s financials.